1. INTRODUCTION {#sec1}
===============

1.1. Prescription Pattern {#sec1.1}
-------------------------

A prescription-based study is known as an effectual and a helpful method to examine the prescribing pattern of the physicians \[[@r1]\].

Irrational prescribing of a drug during the treatment of many diseases is a common practice worldwide; it also results in increased morbidity, mortality and also the economic burden on the society \[[@r2]\].

Hypertension is one of the prime chronic diseases. Over 972 million people in the world suffer from this problem, posing a high risk of mortality and morbidity \[[@r3], [@r4]\]. In Saudi Arabia also, it has affected a considerable proportion of the population, being one of the prevalent risk factors. The urban population is on par in prevalence with 27.9%, when compared with the rural population with a prevalence of 22.4% \[[@r5]\].

Anti-hypertensive agents should therefore be selected primarily based on their comparative ability to prevent complications like coronary artery disease, congestive heart failure, chronic kidney disease, diabetes mellitus to mention a few \[[@r6]\]. Recommendations of various guidelines are available, which provide algorithms for the treatment as per the stages of hypertension \[[@r7]\]. The purpose of these guidelines is to amalgamate the available scientific evidence and offer guidance to burdened primary care clinicians.

There is a guideline known as the JNC-8 (Eighth Joint National Committee) which has recently released protocols that are evidence-based for the treatment, their goals as well as the drugs used in the management of hypertension in adults and the guideline is to be followed by the physicians all around the world. According to these guidelines, the initial drugs of choice for hypertension are in a sequence of ACE inhibitor (ACEI), Angiotensin receptor blocker (ARB), Thiazide diuretic and then Calcium channel blocker (CCB).

Whereas, there is another guideline which is followed specifically in Saudi Arabia known as "The Saudi Hypertension Guidelines". According to the guidelines, approaches towards the management of hypertensive patients include interventions for treating elevated blood pressure and other cardiovascular risk factors which can be reversible. This can be achieved by lifestyle modifications, in most of the cases, we may need drug therapy. The therapy should be initiated for patients with uncomplicated HTN with any of these agents: THZ-Ds, ACE-Is, CCBs, βBs (for patients \< 60 years of age), ARBs .

Bakare OQ *et al*. (2016) and Krishna M (2015) conducted a similar study on the use of anti-hypertensives and concluded that the prescribers followed the JNC-7 guidelines \[[@r7], [@r8]\].

Whereas a similar study was conducted by Bipin BP *et al*. and Shukrala F, Gabriel T (2015) which stated that their prescribers were not following the JNC-7 guidelines \[[@r9], [@r10]\]. Whereas a study conducted by Jarari N (2015) stated that there was a need of special attention to the management of hypertension and also recommended to follow standard guidelines for prescribing anti-hyper- tensives so as to promote their rational use \[[@r11]\].

Taking into consideration the importance of rational medication use and the impact of following the treatment guidelines, the present study was designed to analyze the prescribing patterns of anti-hypertensives and to determine their adherence to the guidelines.

1.2. Aim of the Study {#sec1.2}
---------------------

This study basically aims to assess the drug prescribing pattern of antihypertensive agents in patients with only hypertension as well as in patients with both hypertension and diabetes mellitus and check whether the current prescribing pattern of anti-hypertensives is in accordance with JNC-8 (Eighth Joint National Committee) and Saudi hypertension guidelines or not.

2. MATERIALS AND METHODS {#sec2}
========================

2.1. Method of Data Collection {#sec2.1}
------------------------------

A retrospective cross-sectional observational study was conducted in two different hospitals in Aseer region of Abha, Saudi Arabia. Ethical approval was also obtained to carry out our study.

A sample size of 122 out-patient prescriptions was collected from the patients diagnosed with only hypertension and with hypertension and diabetes mellitus of both the genders. The targeted sample size was calculated by using a Raosoft sample size calculator (<http://www.raosoft.com/samplesize.html>) with a predetermined margin of error of 5% and a confidence level of 90%. In order to minimize erroneous findings and to increase study reliability, the mínimum target sample size was set at 271. The sample size was based on the inflow of patients to those hospitals and the variance of Aseer región population as mentioned in the annual Health statistic book 2016, published by the Ministry of Health, Saudi Arabia \[[@r12]\]. The targeted subjects were included by the non-probability convenience sampling technique in this study.

### 2.1.1. Inclusion Criteria {#sec2.1.1}

i.  Patients of age 18 years and above of both the genders.

ii. Prescriptions with the diagnosis of hypertension alone and with hypertension and diabetes mellitus.

### 2.1.2. Exclusion Criteria {#sec2.1.2}

Pregnant women were excluded from this study.

A specially designed proforma was used for data collection was which constituted of part A: the patient's demographic details (Age, Gender, Ht, Wt), BP, comorbidity and in part B: antihypertensive drugs prescribed in patients diagnosed with hypertension and patients with both hypertension and diabetes mellitus.

The variables taken into consideration were age, gender, patients with comorbidity diabetes mellitus, drug therapy (monotherapy, two-drug combination, three-drug combination).

2.2. Tool of Research {#sec2.2}
---------------------

-   Medical prescriptions of patients were used to obtain diagnostic, demographic and drug use information.

-   An appropriate structured data collection form was used to carry out this study.

This form was comprised of 2 sections;

Section A: It included details about the demographic variables of the subject.

Section B: Antihypertensive drugs prescribed in patients diagnosed with hypertension and patients with both hypertension and diabetes mellitus.

2.3. Method of Data Analysis {#sec2.3}
----------------------------

A descriptive statistical analysis method was used to calculate the percentage of the anti-hypertensives as a single-drug therapy, two-drug combination, three-drug combination therapy being used in patients with only hypertension and hypertension and diabetes mellitus by using MS-Excel 2013 and SPSS. A correlation study was carried out to compare the studies which were in accordance with the guidelines.

3. RESULTS {#sec3}
==========

3.1. Gender Wise Distribution of Patients {#sec3.1}
-----------------------------------------

Out of 122 prescriptions which we collected during our study, males were 71 *i.e* (58%) and  females were 51 *i.e* (42%) diagnosed with  hypertension alone and hypertension and diabetes mellitus.

3.2. Age-wise Distribution of Patients {#sec3.2}
--------------------------------------

In this study, we found that most of the patients belonged to the age-group of 56-65years, followed by the age-group of 66-75 years. We found that very few people belonged to the age-group of more than 96 years. So we could say that HTN was the most prevalent in the age-group of more than 55 years.

3.3. Distribution of Mono-drug Therapy in Patients with only HTN {#sec3.3}
----------------------------------------------------------------

From this Table (**[1](#T1){ref-type="table"}**) we can conclude that most of the patients were frequently prescribed with ACEI or CCB in (32%) patients as a choice of drug as a mono drug therapy regimen. Whereas the other drug categories like ARB (16%), and beta-blockers (13%) were prescribed less frequently. The least frequently prescribed drug category in mono-drug therapy was diuretics in (7%) of patients.

3.4. Distribution of Mono-drug Therapy in Patients with HTN + DM {#sec3.4}
----------------------------------------------------------------

ACEI (52%) were the most frequently prescribed drug as a monotherapy in patients diagnosed with HTN and also had a comorbidity DM followed by CCB (21%), ARB (14%), beta-blockers (10%), whereas THZ-D were least frequently prescribed (3%) as shown in Table (**[2](#T2){ref-type="table"}**).

3.5. Percentage of 2-drug Regimen Prescribed in Patients with HTN, HTN+DM {#sec3.5}
-------------------------------------------------------------------------

This Table (**[3](#T3){ref-type="table"}**) explained about the anti-hypertensives used as a 2-drug therapy combination. The most frequently used drugs as 2 drug therapy were ACEI+ Beta-blockers (29%). Beta-blockers were the drugs of choice in most of the combinations as well as CCB were mostly used as a combination in 2-drug therapy regimen. The combination of drugs that were prescribed very rarely was CCB+ACEI (3%), diuretics (3%).

3.6. Percentage of 3-drug Regimen Prescribed in Patients with HTN, HTN+DM {#sec3.6}
-------------------------------------------------------------------------

It is shown in Table (**[4](#T4){ref-type="table"}**) he most commonly prescribed drug category of anti-hypertensives used in 3 drug therapy is beta-blockers + ARB along with either THZ-D or CCB (18%). We could notice that beta-blockers were the most commonly prescribed along with other drug categories in 3-drug regimen followed by CCB.

4. DISCUSSION {#sec4}
=============

In our study, we collected a total of 122 prescriptions of outpatients diagnosed with HTN and HTN+DM.

According to our findings, hypertension and HTN+DM were more prevalent in males than in females, with prevalence increasing with age. This is similar to the study conducted by Jhaj *et al* (2001) and Malhotra *et al*. (2001) in India \[[@r13], [@r14]\].

ACE-Inhibitors were the most frequently prescribed class of drugs as mono therapy in patients with HTN as well as HTN+DM which clearly shows that the prescribers follow the JNC-8 guidelines as well as Saudi HTN guidelines in case of mono-therapy.

Whereas beta blockers were most commonly used in 2-drug therapy and 3-drug therapy which is not in accordance with both the guidelines.

These results were anomalous to the study conducted by Krishna M *et al*. in 2015 where the most commonly prescribed drug in mono,2-drug and 3 drug therapy was THZ-Diuretics \[[@r7]\].

In patients with HTN + DM, the most commonly prescribed drug in 2-drug and 3-drug therapy class is THZ-Diuretic.

So we could come to a conclusion that JNC-8 guidelines as well as Saudi HTN guidelines were followed in monotherapy but not in 2-drug regimen and 3-drug regimen.

CONCLUSION
==========

After analyzing the study, we conclude that the prescription pattern of anti-hypertensives in Aseer Region of Saudi Arabia is in compliance with the JNC-8(Eighth Joint National Committee) guidelines as well as the Saudi hypertension guidelines to a partial extent only.

Most of the prescriptions were rational, but further improvement is required. In future, studies that focus on the rationale for the choice of the drug based on demographic data, economic status, associated conditions and complications would give additional insights into prescribing patterns in hypertension.

Rational prescribing requires consideration to dose and duration as well as the interaction with other medications.

The principal limitation of our study was that it was conducted on outpatients and was a retrospective study which restricted us in retrieving some more parameters. A therapeutic audit with more parameters of analysis to provide regular feedback to researchers and prescribers may encourage rational prescribing in hypertension.

As per our conclusion, the prescribing patterns in Aseer region need to be improved. Prescribers can be educated by performing seminars, promoting ongoing staff education and training to promote rational prescribing which in turn prevents further complications thus increasing the quality of life of the patients.

The authors would like to thank the class of 2016 for completing this survey.

ACEI

:   Angiotensin Converting enzyme inhibitor

ARB

:   Angiotensin Receptor blocker

BP

:   Blood pressure

CCB

:   Calcium channel blocker

CVR

:   Cardiovascular risk

DASH

:   Dietary Approaches to Stop Hypertension

DBP

:   Diastolic blood pressure

DM

:   Diabetes Mellitus

HTN

:   Hypertension

JNC

:   8-Eighth Joint National Committee

SBP

:   Systolic blood pressure

THZ

:   D-Thiazide Diuretic

βBs

:   Beta-blockers

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
==========================================

The ethical approval has been obtained from the research ethics committee, College of Medicine, King Khalid University, Abha, Saudi Arabia. Approval no: (REC \# 2017-02-24).

HUMAN AND ANIMAL RIGHTS
=======================

Not applicable.

CONSENT FOR PUBLICATION
=======================

The consent for publication was obtained from the patients as well as the institution.

AVAILABILITY OF DATA AND MATERIALS
==================================

The authors do not wish to share the data because of confidentiality and legal issues of the Hospital in which the study was carried out in.

FUNDING
=======

None.

CONFLICT OF INTEREST
====================

The authors declare no conflict of interest, financial or otherwise.

###### Distribution of mono drug therapy in patients with only HTN.

  **Drug Category**                                 **Percentage Use (%) of Mono Drug Therapy in Patients with only HTN**
  ------------------------------------------------- -----------------------------------------------------------------------
  Angiotensin converting enzyme inhibitors (ACEI)   32
  Calcium channel blockers(CCB)                     32
  Beta Blockers                                     13
  Angiotensin II receptor blockers (ARBs)           16
  Diuretics                                         7

###### Distribution of mono drug therapy in patients with HTN + DM.

  **Drug Category**                                 **Percentage Use (%) of Mono Drug Therapy in Patients with HTN + DM**
  ------------------------------------------------- -----------------------------------------------------------------------
  Angiotensin-converting enzyme inhibitors (ACEI)   52
  Calcium channel blockers(CCB)                     21
  Beta Blockers                                     10
  Angiotensin II receptor blockers (ARBs)           14
  Thiazide Diuretics                                3

###### Percentage of 2-drug regimen prescribed in patients with HTN, HTN+DM.

  -----------------------------------------------------------------------------------
  **Drug Category**                     **Percentage Use (%) of 2-Drug Regimen**\
                                        **Prescribed in Patients with HTN, HTN+DM**
  ------------------------------------- ---------------------------------------------
  ACEI+ ARB                             3

  ACEI+ Beta blockers                   29

  ARB+ Beta blockers                    7

  ARB+ Thiazide Diuretics               19

  CCB+ACEI                              10

  CCB+ARB                               7

  CCB+ Beta blockers                    6

  CCB+ Thiazide Diuretics               10

  Beta blockers+ Loop diuretics         6

  Loop diuretics+ K-sparing diuretics   3
  -----------------------------------------------------------------------------------

###### Percentage of 3-drug regimen prescribed in patients with HTN, HTN+DM.

  ---------------------------------------------------------------------------------------------------
  **Drug Category**                         **Percentage Use (%) of 3-Drug Regimen Prescribed in**\
                                            **Patients with HTN, HTN+DM**
  ----------------------------------------- ---------------------------------------------------------
  2 Betablockers + ACEI                     4

  Betablocker+ ACEI+ THZ-D                  13

  Betablocker+ ARB+ ACEI                    4

  Betablocker+ ARB+ THZ-D                   18

  Betablocker+ THZ-D+ K-sparing diuretics   13

  CCB+ ACEI+ THZ-D                          9

  CCB+ ARB+ THZ-D                           13

  CCB+ Beta blockers + ACEI                 4

  CCB+ Beta blockers + ARB                  18

  CCB+ Beta blockers + Loop diuretics       4
  ---------------------------------------------------------------------------------------------------
